Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline

For a gene ther­a­py tech up­start that launched out of stealth mode just 5 months ago with big goals and not a tremen­dous amount of launch mon­ey, Dyno Ther­a­peu­tics has quick­ly moved it­self in­to a front­line of­fen­sive in R&D — work­ing in league with some of the mar­quee de­vel­op­ers in the field.

Build­ing on al­liances with No­var­tis and Sarep­ta, the glob­al Roche/Genen­tech group has now stepped in with the lat­est dis­cov­ery deal, will­ing to wa­ger up to $1.8 bil­lion that the spin­out from George Church’s lab at Har­vard has what it takes to de­liv­er on AAV 2.0. There’s an up­front, but the part­ners are keep­ing that part mum. But while most ear­ly-stage deals are heav­i­ly back end­ed, there’s a big enough num­ber here to make a dif­fer­ence on the bank bal­ance.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN